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Uremia does not affect neointima 
formation in mice
Annemarie Aarup1, Carsten H. Nielsen2, Line S. Bisgaard1, Ilze Bot  3, Henrik H. El-Ali2, 
Andreas Kjaer  2, Lars B. Nielsen1,4 & Tanja X. Pedersen1
Atherosclerotic cardiovascular disease is a major complication of chronic kidney disease (CKD). CKD 
leads to uremia, which modulates the phenotype of aortic smooth muscle cells (SMCs). Phenotypic 
modulation of SMCs plays a key role in accelerating atherosclerosis. We investigated the hypothesis 
that uremia potentiates neointima formation in response to vascular injury in mice. Carotid wire injury 
was performed on C57BL/6 wt and apolipoprotein E knockout (Apoe−/−) mice two weeks after induction 
of uremia by 5/6 nephrectomy. Wire injury led to neointima formation and downregulation of genes 
encoding classical SMC markers (i.e., myocardin, α-smooth muscle actin, SM22-alpha, and smooth 
muscle myosin heavy chain) in both wt and Apoe−/− mice. Contrary to our expectations, uremia did not 
potentiate neointima formation, nor did it affect intimal lesion composition as judged from magnetic 
resonance imaging and histological analyses. Also, there was no effect of uremia on SMC marker gene 
expression in the injured carotid arteries, suggesting that there may be different effects of uremia 
on SMCs in different vascular beds. In conclusion, uremia does not accelerate neointima formation in 
response to wire injury of the carotid artery in mice.
Chronic kidney disease (CKD) is characterized by loss of kidney function and leads to accumulation of waste 
products in the blood, i.e. uremia1, 2. The number of patients with decreased kidney function is rising worldwide, 
partly caused by the increased prevalence of diabetes3, 4. Cardiovascular disease is a major complication for CKD 
patients and accounts for more than 50% of deaths in dialysis-dependent patients5, 6. This is in part due to accel-
erated atherosclerosis7. Even slightly reduced renal function, which affects more than 10% of the population, is 
associated with increased atherosclerosis and cardiovascular mortality8–12. The association between CKD and 
cardiovascular disease cannot solely be explained by traditional cardiovascular risk factors8, 13. Decreased kid-
ney function is an independent risk factor for development of atherosclerotic lesions7, and statin treatment has 
reduced effects in patients with advanced CKD14. Thus, studies investigating the mechanisms behind the acceler-
ated atherosclerosis in uremia are warranted.
To enable such analyses, a mouse model in which moderate uremia accelerates atherosclerosis has been estab-
lished15–17. Using this model, it was shown that uremic atherosclerosis is associated with degenerative changes in 
the aortic tunica media of hyperlipidemic apolipoprotein E knockout (Apoe−/−) mice18.
In the healthy artery, the tunica media largely consists of contractile vascular smooth muscle cells (SMCs). 
SMCs possess enormous plasticity, and play an important role in the development of classical atherosclerosis. 
Upon vascular injury, e.g. atherosclerosis or carotid wire injury, SMCs undergo phenotypic modulation from 
a quiescent “contractile” state to a more dedifferentiated “synthetic” state. This phenotypic shift is accompa-
nied by reduced expression of SMC marker proteins, such as the transcription co-factor myocardin (MYOCD), 
smooth muscle alpha actin (ACTA2), smooth muscle 22-alpha (TAGLN) and smooth muscle myosin heavy chain 
(MYH11)19, 20. In the synthetic state, SMCs become proliferative, migratory, lose contractility, and increase the 
synthesis of extracellular matrix proteins21. SMCs display immense plasticity, not only within the SMC pheno-
types, but also with the ability to transdifferentiate into e.g. macrophage-like cells22, 23. Cholesterol uptake by 
SMCs induces downregulation of classical SMC markers and a more macrophage-like phenotype22. Recent line-
age –tracing studies have shown that more than 80% of cells with SMC origin are not ACTA2 positive, and that 
30% of cells classified as macrophages originate from SMCs in mouse atherosclerotic lesions24. Hence, although 
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SMC modulation is important for vessel repair in response to injury, it also contributes substantially to devel-
opment of diseases of the vascular wall. This suggests that SMCs may play a more pro-atherogenic role than 
previously believed.
We have recently observed that uremia leads to downregulation of contractile SMC marker genes both in 
areas with and without atherosclerotic lesions25. This downregulation was consistent in normocholesterolemic 
wild type mice, in which the contractility of the uremic aorta was also reduced. Furthermore, serum from CKD 
patients decreases mRNA expression of contractile genes, and increases proliferation of aortic SMCs26. Together, 
these observations indicate that uremia may directly affect phenotypic modulation of SMCs. Given the emerging 
evidence that SMCs play important roles in vascular injury, we hypothesized that uremia-mediated phenotypic 
modulation of SMCs plays a key role in uremic vasculopathy. To test this hypothesis, we performed carotid wire 
injury in uremic wild type and Apoe−/− mice.
Results
Uremia does not affect neointima formation in C57BL/6 mice. To investigate the effect of uremia 
on neointima formation in wild type C57BL/6 (wt) mice, uremia was induced by 5/6 nephrectomy (NX). Control 
mice were sham operated (Sham). One week after the operations, NX induced increased plasma urea (2.2 fold, 
p < 0.0001), phosphate (1.2 fold, p < 0.01), and cholesterol (1.2 fold, p < 0.01) compared to sham-operated con-
trols (Table 1). Two weeks after induction of uremia, mice underwent carotid wire injury (WI) in the left carotid 
artery, and the right carotid artery served as a control (Fig. 1A).
We had previously performed a pilot study comparing wall thickness measurements obtained using either 
magnetic resonance imaging (MRI) or histology in non-uremic wt mice. These analyses suggested that MRI can 
be used to compare neointima formation in vivo between groups of mice (Fig. 2B). Mice with blood clots in the 
carotids as judged by MRI were excluded (representative picture in Fig. 2A).
The carotid wall area was similar in NX and sham mice as measured by MRI four weeks after WI (Suppl. 
Fig. 1A). Based on this observation, the study was continued for two weeks. A significant difference in wall area 
between injured and control carotids was detected six weeks after WI (Suppl. Fig. 1B). However, there was no 
difference in the carotid wall area between NX and sham mice as determined by MRI and histology (Fig. 1B). This 
lack of effect of uremia was observed at three different anatomical locations (Fig. 1C). Also, we observed no dif-
ference in carotid medial or intimal areas between sham and NX mice (Fig. 1E,F). Based on immunohistochem-
istry, the content of α -SMA positive SMCs in injured carotid sections of NX and sham mice was similar (Suppl. 
Fig. 2A, top). There were no macrophages in the lesions as judged by MOMA-2 staining (Suppl. Fig. 2B, top).
As expected, mRNA markers of the contractile SMC phenotype were reduced in injured compared to control 
carotids (Fig. 3). Apart from Tagln mRNA expression, which displayed a statistically significant reduction in 
the uninjured control carotids of NX mice, NX did not affect mRNA expression of the SMC genes in control or 
injured carotids (Fig. 3).
Uremia does not affect neointima formation in Apoe−/− mice. To address whether hypercholes-
terolemia potentiates neointima formation in itself, and potential effects of uremia on neointima formation, we 
performed a WI study in Apoe−/− mice (Fig. 4A). NX increased plasma urea (2 fold, p < 0.0001), and calcium 
(p < 0.05); there was no effect on plasma phosphate or cholesterol (Table 1). One week after induction of uremia, 
mice were shifted to a western-type diet for the remainder of the study. Two weeks after induction of uremia, 
all mice underwent carotid WI. Four weeks later (eight weeks after NX), NX mice had a 2.2 fold increase in 
plasma urea (p < 0.0001) compared to sham mice. Also, calcium and cholesterol concentrations were significantly 
increased in NX mice (Table 1). As anticipated, the carotid lesions were substantially larger in Apoe−/− than in wt 
mice (Fig. 1D and Fig. 4B). However, NX did not affect development of vascular lesions after WI in Apoe−/− mice 
(Fig. 4C,D). This lack of effect of NX was seen at four different anatomical locations in the injured area of the 
carotid artery (Suppl. Fig. 3A and B).
Based on histology, the composition of the vascular lesions in terms of macrophage, SMC, and collagen con-
tent was similar in carotid lesions from NX and sham mice (Suppl. Fig. 2A and B, bottom, depicts immunohisto-
chemical stainings).
As in wt mice, the expression of mRNA markers of the contractile SMC phenotype was downregulated in 
injured compared to control carotids (Acta2, Myocd, Tagln and Myh11), and expression levels were similar in 
injured carotids from sham and NX Apoe−/− mice (Fig. 5). Furthermore, we assessed the expression of markers of 
C57BL/6 Apoe−/− 1 week after NX Apoe−/− 8 weeks after NX
Sham 5/6 NX Sham 5/6 NX Sham 5/6 NX
n 13 12 12 20 12 20
Body weight (g) 23.5 ± 0.5 23.3 ± 1.1 20.5 ± 0.4 21.2 ± 0.2 23.5 ± 0.6 23.2 ± 0.3
P-Urea (mM) 8.9 ± 0.4 19.2 ± 1.6**** 9.8 ± 1.3 20.1 ± 1.7*** 6.1 ± 03 17.4 ± 2.5**
P-Calcium (M) 2.3 ± 0.0 2.6 ± 0.0**** 2.5 ± 0.1 2.8 ± 0.0* 2.3 ± 0.0 2.5 ± 0.0**
P-Phosphate (mM) 2.2 ± 0.1 2.7 ± 0.1** 1.9 ± 0.1 1.7 ± 0.1 2.2 ± 0.1 2.3 ± 0.1
P-Cholesterol (mM) 2.3 ± 0.1 2.7 ± 0.1** 10.3 ± 0.8 12.8 ± 1.1 25.8 ± 1.5 32.3 ± 1.8*
P-Osteopontin (ng/ml) — — — — 264.5 ± 30 643.4 ± 63***
Table 1. Basic characteristics of uremic (5/6 NX) and sham-operated (sham) mice. Values represent 
mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; Sham vs 5/6 NX, t-test.
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Figure 1. Uremia does not affect neointima formation in carotid arteries after vascular injury in C57BL/6 
mice. (A) Study outline: C57BL/6 mice underwent 5/6 nephrectomy (NX) or sham operations in two steps 
(timepoints NX1 and NX2), and subsequently carotid wire injury and magnetic resonance imaging (MRI).  
(B) Quantification of cross-sectional vascular wall area by in vivo MRI (average of 4 cross-sections/mouse; n = 5 
NX and n = 4 sham) and histology (average of 8–12 sections/mouse; n = 11 NX and n = 8 sham) in injured 
carotids of NX and sham C57BL/6 mice 6 weeks after wire injury. (C) Quantification of carotid wall area by 
histology. Three anatomical locations, series 1–3 (S1–S3, 2–4 sections/mouse/per series, n = 11 NX and n = 8 
sham), were quantified. (D) Representative pictures of Trichrome stained injured and control carotid arteries 
from NX and sham mice. Scale bar, 200 μm. (E) Quantification of cross-sectional intimal and (F) medial area in 
injured and control carotid arteries from NX and sham mice (average of 8–12 sections/mouse, n = 11 NX and 
n = 8 sham). Data are presented as mean ± SEM. Unpaired t-test (B) with correction for multiple comparisons 
(C), 1-way ANOVA followed by Sidak’s multible comparison test (E,F). *P < 0.05.
Figure 2. Magnetic resonance imaging on carotid arteries. (A) In vivo magnetic resonance imaging (MRI) and 
H&E staining from a C57BL/6 mouse subjected to wire injury in the left carotid artery. Following wire injury, 
the right carotid artery (control) appeared normal, whereas a blood clot obstructed the entire left (injured) 
carotid artery. (B) Correlation between MRI measurements and histological measurements of cross-sectional 
areas of injured carotid arteries. Values are averaged from 4 MRI cross-sections or 6–10 histological sections. 
n = 18. A statistically significant (p = 0.0045) correlation between MRI measured values and histology-derived 
values was found.
www.nature.com/scientificreports/
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endothelial cells, macrophages, and inflammation (platelet and endothelial adhesion molecule 1 (Pecam1), von 
Willebrand factor, interleukin-6, tumor necrosis factor α, F4/80, C-C chemokine receptor type 7). NX did not 
affect mRNA expression of any of these markers (data not shown). Pecam1 expression was reduced in injured as 
compared to control carotid arteries (Suppl. Fig. 4).
Discussion
This study aimed to assess whether uremia increases neointima formation in normocholesterolemic wt mice 
and hypercholesterolemic Apoe−/− mice by phenotypically modulating SMCs. The present evidence from his-
tological and MRI analyses suggest that uremia affects neither the size nor the composition of the intimal and 
medial areas of injured carotid arteries. The morphological findings were further supported by gene expression 
analyses, since the expression of SMC marker genes were similar in NX and sham carotid arteries. Likewise, 
mRNA expression of endothelial, macrophage, and inflammatory markers was not affected by NX in the carotid 
artery. WI did induce a reduction in mRNA levels of Pecam1. At a first glance, this observation might signify lack 
of re-endothelialization. However, it might also merely be caused by the increased cellularity of injured carotid 
arteries, with a smaller fraction of endothelial cells compared to uninjured arteries.
Several previous observations supported the hypothesis that uremia would potentially increase neotintima 
formation by modulating the SMC phenotype. We have observed that Myocd and its target genes are downregu-
lated in uremic aortas25. Reduction of Myocd is also seen in carotid arteries following wire injury, and viral overex-
pression of Myocd after carotid wire injury reduces neointima formation in mice20. Furthermore, overexpression 
of mir146a, which is increased in aortas of uremic mice25, promotes intimal hyperplasia in rats27. Also, vascular 
neointima formation is accelerated in arteriovenous fistulas in uremic rodents28, 29. However, as evident from 
the present study, uremia does not increase neointima formation in wt or Apoe−/− mice after carotid wire injury.
What is the explanation for these negative findings? Gene expression analyses in both wt and Apoe−/− mice 
indicate that wire injury in itself leads to phenotypic modulation of SMCs. As such, Myocd, Acta2, Tagln, and 
Figure 3. Wire injury, but not uremia, affects expression of smooth muscle marker genes in C57BL/6 mice. 
Real-time PCR analysis of carotid mRNA (pooled two and two) from sham-operated (sham) and uremic (NX) 
C57BL/6 mice, either with (Injured) or without (Control) wire-induced vascular injury. Gene expression was 
normalized to CANX. Bars indicate mean ± SEM (n = 6 per group); 1-way ANOVA followed by Sidak’s multible 
comparison test, *p < 0.05, **p < 0.1, ***p < 0.001,****p < 0.0001. a.u.: arbitrary units; Acta2: Smooth muscle 
alpha actin; Myocd, Myocardin; Tagln, SM22 alpha; Myh11, Smooth muscle myosin heavy chain.
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Myh11 were downregulated in injured vs control arteries. Also, neointima formation was induced upon wire 
injury. To our surprise, the gene expression analyses showed no uremia-mediated effects on expression of the 
SMC genes in the carotid control arteries in wt or Apoe−/− mice (apart from Tagln, which was downregulated 
by NX in control arteries in wt mice). This is in contrast to previous data in aortic SMCs 16, 18, 25, 26, in which ure-
mia altered mRNA expression of classical SMC marker genes. The gene expression differences observed in the 
previous vs the present study may thus relate to the different vascular beds examined, i.e. carotid artery in the 
present study vs aorta/in vitro data in previous studies. Indeed, the embryonic origin of SMCs is not identical in 
all segments of the vascular tree, and SMCs with different embryonic origin might respond differently to the same 
stimuli30.
It should be noted that the mice in our study are only mildly-moderately uremic. Hence, this uremic pheno-
type may not correspond to the phenotype observed in patients suffering from end-stage renal disease, which are 
at extreme risk of dying from CVD5. Furthermore, we cannot rule out the possibility that uremia-mediated effects 
on neointima formation could have been observed if mice had been uremic for a longer period of time. However, 
previous observations suggest that a mere two weeks of uremia increase systemic inflammation and phenotypic 
modulation of aortic SMCs24, both of which are key components in neointima formation after carotid wire injury. 
Thus, the six-seven weeks of uremia in the present study should be ‘sufficiently long’ to detect effects on carotid 
neointima formation.
In conclusion, our study show that uremia does not affect neointima formation in response to carotid wire 
injury in wt and Apoe−/− mice, possibly because uremia does not affect phenotypic modulation of SMCs in this 
vascular bed.
Materials and Methods
Mice. Female C57BL/6 (C57BL/6Ntac) and Apoe−/− (C57BL7&Jbom-Apoetm1Unc) mice (Taconic, Ejby, 
Denmark) were housed under a 12 hour light/dark cycle in a temperature controlled room (21–23 °C) with free 
access to standard chow or western diet (D12079B, Research Diets Inc.) as indicated in the text. Animal exper-
iments were performed according to the principles stated in the Danish law on animal experiments and were 
approved by the Animal Experiment’s Inspectorate, Ministry of Environment and Food, Denmark (permission 
Figure 4. Uremia does not affect neointima formation in carotid arteries after vascular injury in Apoe−/− mice. 
(A) Study outline: Apoe−/− mice underwent 5/6 nephrectomy (NX) or sham operation (sham) in two steps 
(timepoints NX1 and NX2), were put on a western diet, and subsequently underwent carotid wire injury. B. 
Representative pictures of Trichrome stained injured carotid arteries from NX and sham Apoe−/− mice. Scale 
bar, 200 μm. (C) Histological quantification of cross-sectional intimal and (D) medial area in injured carotid 
arteries from NX and sham Apoe−/− mice (average of 8–12 sections per mouse; n = 16 NX, n = 7 sham), four 
weeks after wire injury. Horizontal bars represent mean values. Upaired t-test.
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no. 2013-15-2934-00773). The investigation conforms to the Guide for the Care and Use of Laboratory Animals 
published by the European Parliament [EU directive 2010/63/EU].
Surgeries were performed under anesthesia with Zoletil (Tiletamin 1,63 mg/mL, Zolazepam 1,63 mg/mL, 
Xylazin, 2,61 mg/mL, Butorphanoltartrat 0,065 mg/mL) at a dose of 0.01 mL/g body weight. Analgesia (buprenor-
phine 0.001 mg/10 g body weight) was administered subcutaneously twice daily for up to three days after the 
surgical procedures.
5/6 Nephrectomy. Uremia was induced by 5/6 nephrectomy (NX) in a two-step surgical procedure as pre-
viously described15, 31. Briefly, both poles of the right kidney were resected leaving an intact kidney segment, and 
two weeks later the entire left kidney was removed. Control mice underwent sham-operations exposing first the 
right kidney and two weeks later the left kidney. After kidney manipulation or exposure, the peritoneum was 
sutured with 4-0 sutures and the skin incision with 3-0 sutures.
Carotid artery wire injury. All mice underwent transluminal wire injury of the left common carotid 
artery (CCA) with a 0.36 mm flexible guide wire (Hi-Torque balance middleweight, Abbot, 1001780-HC). The 
left CCA was exposed via a midline incision at the ventral side and the bifurcation located. Silk ligatures (6-0, 
PERMA-HAND, Ethicon) were placed around the external carotid artery and distally around the CCA. Two 
sutures were placed around the internal carotid artery, which was then tied off with the distal ligature. An incision 
hole was made between the two ligatures and the guidewire was introduced via the incision hole into the CCA. 
Denudation was achieved by 3 passes along the vessel and 3 rotational passes. The proximal ligature was tied off 
and blood flow restored. The skin incision was closed using 4-0 sutures.
Animals were euthanized 4–6 weeks after wire injury. Mice were anaesthetized with Zoletil (0.01 mL/g), bled 
from the orbital plexus and perfused with cold saline. Carotids were cut in two and the upper section was divided 
Figure 5. Wire injury, but not uremia, affects expression of smooth muscle marker genes in Apoe−/− mice. 
Real-time PCR analysis of carotid RNA (pooled two and two) from sham-operated (sham, n = 5) and uremic 
(NX, n = 10) Apoe−/− mice with (Injured) or without (Control) wire-induced vascular injury. Gene expression 
was normalized to CANX. Bars indicate mean ± SEM. 1-way ANOVA followed by Sidak’s multible comparison 
test, *p < 0.05, **p < 0.1, ***p < 0.001,****p < 0.0001. a.u.: arbitrary units. Acta2: Smooth muscle alpha actin; 
Myocd: Myocardin; Tagln: SM22 alpha; Myh11: Smooth muscle myosin heavy chain.
www.nature.com/scientificreports/
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into two pieces. The upper piece was fixed in 4% formaldehyde for 30 minutes, transferred to cryoembedding 
media (Tissue-Tek® O.C.T.) and frozen. The lower part was snap frozen for RNA analysis.
Plasma measurements. Blood was collected in heparinized microtubes and centrifuged at 4000 rpm for 
10 min at 4 °C. Plasma concentrations of urea, creatinine, phosphate, and cholesterol were measured on a Cobas® 
8000 modular analyzer series (Roche A/S). Plasma concentrations of osteopontin were measured with the quan-
tikine mouse osteopontin immunoassay (MOST00) according to the manufacturer’s instructions (R&D Systems, 
Abingdon, UK).
MRI. Anatomical MR images were acquired on a BioSpec 7 T/16 cm system (Bruker) running Paravision 5.1 
(Bruker). T2-weighted proton density scan was obtained using a multi-slice multi-echo sequence (MSME-PD-T2) 
and a 30 mm surface RF coil. The following parameters were used: TR = 2000 ms, TE 13/65 ms, 1 average, 10 
slices, slice thickness 0.60 mm, inter slice distance 0.60 mm, in plane pixel size 97.7 × 97.7 µm. Images were 
acquired in the axial plane. Image analysis was performed in Horos v2.0.1. The area of the carotid artery wall was 
estimated by drawing region of interests (ROIs) covering the outer artery wall and subtracting the area for ROIs 
drawn over the lumen.
Histology. Starting at the bifurcation, 10 um thick sections were collected in series of 5 glass slides 
(SuperFrost Plus slides, Menzel-Glaser, Germany) with 4 sections per glass. For wt mice, each series was sep-
arated by 100 um. For morphometry, 1 glas from 3–4 subsequent series were stained with Masson’s trichrome 
(Sigma-Aldrich, HT15-1KT) according to the manufactures instructions. Intimal and medial areas were quan-
tified and the collagen-positive area was determined as the percentage of blue-staining using the image analyses 
software Visiopharm (Visiopharm, Hørsholm, Denmark).
To stain macrophages, we performed anti-MOMA-2 immunohistochemistry as previously described32 with 
the following modifications: Sections were incubated with primary MOMA-2 antibody (rat anti-mouse IgG2b, 
Serotec, Düsseldorf, Germany, MCA519) diluted 1:300 overnight at 4 °C.
To stain smooth muscle cells, a biotinylated primary antibody (Actin, smooth Ab (clone 1A4); MS-113- B1; 
Neomarkers, Freemont, CA, USA) was applied. Endogenous peroxidase activity was blocked with 0.5% H2O2, 
rinsed in dH2O and antigen retrieval was obtained with proteinase K treatment for 2 minutes and rinsed in TBS-T, 
and unspecific binding was blocked with 2% BSA. Sections were incubated with primary antibody (0.2 ug/ml in 
1% BSA in TBS) over night at 4 °C. After rinse in TBS-T, antibody binding was detected with the Vectastain, Elite 
ABC kit (VWR, Denmark, PK6100) and DAB (Dako), and sections were counterstained with Mayer’s haematox-
ylin. MOMA-2 and α-SMA staining was scored independently by two investigators from 0–3 based on area and 
intensity.
For CD31 staining, endogenous peroxidase was blocked with 0.5% H2O2, antigen retrieval was obtained with 
proteinase K treatment, and sections were blocked with 2% BSA in TBS-T for 1 hour. Sections were incubated 
with primary anti-Cd31 antibody (ab28364, Abcam; 0.5 ug/ml) over night at 4 °C, and the EnVision System 
HRP-labeled Polymer anti-rabbit (Dako, K4002) followed by DAB (Dako) was used for detection.
RNA extraction and qPCR analyses. To obtain enough RNA for subsequent analyses, carotid samples 
were pooled two and two, the tissue was homogenized on a Tissuelyzer, and RNA was extracted using a mirRNe-
asy Micro Kit (Qiagen, 217084E). RNA quality was assessed on a BioAnalyzer (Agilent Technologies Denmark 
A/S, Naerum, Denmark) using an RNA 6000 Nano Assay Kit and RNA concentration was determined on nano-
drop. For mRNA analyses, cDNA was made from 54–75ng RNA with High Capacity cDNA Reverse Transcription 
Kit (Roche, Applied biosystems, 4368814) in a 10 μl reaction at 37 °C for 120 minutes. Real time PCR was per-
formed on an ABI Prism 7900HT Sequence Detection System. Each reaction mixture contained 1.08–1.5 ng 
cDNA and the ABI Fast SYBR Green Mix or TagMan®Gene Expression master mix (Applied Biosystems) was 
used. Standard curves were made by serial dilution of a pool of all cDNAs. All analyses were done in duplicate, 
and gene expression data were normalized against expression of CANX and ACTB (Primer/Double Dye, DD-mo-
600, Primerdesign). Primer sequences are listed in Suppl. Table 1.
Statistics. Data were analyzed using the Graphpad Prism software, version 7 (GraphPad Inc.). P values were 
calculated using one-way ANOVA following Sidak’s post-hoc test, or unpaired t-test as indicated in the manu-
script. Correction for multiple comparisons was done by the Holm-Sidak test. p < 0.05 was considered significant. 
Values represent mean ± SEM.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
References
 1. Levey, A. S. & Coresh, J. Chronic kidney disease. Lancet 379, 165–180 (2012).
 2. Underwood, C. F. et al. Uraemia: an unrecognized driver of central neurohumoral dysfunction in chronic kidney disease? Acta 
Physiol 1–19, doi:10.1111/apha.12727 (2016).
 3. USRDS. 2014 USRDS Annual Data Report, Volume 2: End-Stage Renal Disease. 187–210 (2014).
 4. Webster, A. C., Nagler, E. V., Morton, R. L. & Masson, P. Chronic Kidney Disease. Lancet 389, 1238–1252 (2017).
 5. Vanholder, R. et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrology Dialysis Transplantation 
20, 1048–1056 (2005).
 6. USRDS. 2015 USRDS Annual Data Report Volume 2: ESRD in the United States, chapter 9: Cardiovascular Disease in patients with 
ESRD. 1–6 (2016).
 7. Olechnowicz-Tietz, S., Gluba, A., Paradowska, A., Banach, M. & Rysz, J. The risk of atherosclerosis in patients with chronic kidney 
disease. Int Urol Nephrol 45, 1605–1612 (2013).
www.nature.com/scientificreports/
8SCIENTIfIC REPORTS | 7: 6496 | DOI:10.1038/s41598-017-06816-6
 8. Stenvinkel, P. et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces 
fit into the uremic puzzle? Clin J Am Soc Nephrol 3, 505–521 (2008).
 9. Hallan, S. I. et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J. Am. Soc. 
Nephrol. 17, 2275–2284 (2006).
 10. Chadban, S. J. et al. Prevalence of kidney damage in Australian adults: The AusDiab kidney study. J. Am. Soc. Nephrol. 14, S131–8 
(2003).
 11. Wen, C. P., Cheng, T., Tsai, M. K., Chang, Y. C. & Chan, H. T. All-cause mortality attributable to chronic kidney disease: a prospective 
cohort study based on 462 293 adults in Taiwan. Lancet. doi:10.1016/S0140-6736(08)60952-6 (2008).
 12. Coresh, J. et al. Prevalence of chronic kidney disease in the United States. Jama-Journal of the American Medical Association 298, 
2038–2047 (2007).
 13. Schneider, A. et al. Determinants of Cardiovascular Risk in Haemodialysis Patients: Post hoc Analyses of the AURORA Study. Am J 
Nephrol 37, 144–151 (2013).
 14. Hou, W. et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic 
review and meta-analysis. European Heart Journal 34, 1807–1817 (2013).
 15. Bro, S. Chronic Renal Failure Accelerates Atherogenesis in Apolipoprotein E-Deficient Mice. Journal of the American Society of 
Nephrology 14, 2466–2474 (2003).
 16. Pedersen, T. X. et al. Osteopontin deficiency dampens the pro-atherogenic effect of uraemia. Cardiovascular Research 98, 352–359 
(2013).
 17. Massy, Z. A. et al. Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J. Am. Soc. 
Nephrol. 16, 109–116 (2005).
 18. Bro, S. Uremia-Specific Effects in the Arterial Media During Development of Uremic Atherosclerosis in Apolipoprotein E-Deficient 
Mice. Arteriosclerosis, Thrombosis, and Vascular Biology 26, 570–575 (2005).
 19. Gomez, D. & Owens, G. K. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovascular Research 95, 156–164 
(2012).
 20. Talasila, A. et al. Myocardin Regulates Vascular Response to Injury Through miR-24/-29a and Platelet-Derived Growth Factor 
Receptor. Arteriosclerosis, Thrombosis, and Vascular Biology 33, 2355–2365 (2013).
 21. Owens, G. K. Molecular Regulation of Vascular Smooth Muscle Cell Differentiation in Development and Disease. Physiological 
Reviews 84, 767–801 (2004).
 22. Feil, S. et al. Transdifferentiation of vascular smooth muscle cells to macrophage-like cells during atherogenesis. Circulation Research 
115, 662–667 (2014).
 23. Vengrenyuk, Y., Nishi, H., Long, X. & Ouimet, M. Cholesterol Loading Reprograms the MicroRNA-143/145–Myocardin Axis to 
Convert Aortic Smooth Muscle Cells to a Dysfunctional Macrophage-Like doi:10.1161/ATVBAHA.114.304029/-/DC1 (2015).
 24. Shankman, L. S. et al. KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque 
pathogenesis. Nat Med 21, 628–637 (2015).
 25. Madsen, M. et al. Uremia modulates the phenotype of aortic smooth muscle cells. Atherosclerosis 257, 64–70 (2017).
 26. Monroy, M. A. et al. Chronic kidney disease alters vascular smooth muscle cell phenotype. Front Biosci (Landmark Ed.) 20, 784–795 
(2015).
 27. Sun, S.-G. et al. miR-146a and Krüppel-like factor 4 form a feedback loop to participate in vascular smooth muscle cell proliferation. 
Nature Publishing Group 12, 56–62 (2011).
 28. Kokubo, T. et al. CKD Accelerates Development of Neointimal Hyperplasia in Arteriovenous Fistulas. Journal of the American 
Society of Nephrology 20, 1236–1245 (2009).
 29. Langer, S. et al. Chronic kidney disease aggravates arteriovenous fistula damage in rats. Kidney Int 78, 1312–1321 (2010).
 30. Majesky, M. W. Developmental Basis of Vascular Smooth Muscle Diversity. Arteriosclerosis, Thrombosis, and Vascular Biology 27, 
1248–1258 (2007).
 31. Pedersen, T. X. et al. Effect of treatment with human apolipoprotein A-I on atherosclerosis in uremic apolipoprotein-E deficient 
mice. Atherosclerosis 202, 372–381 (2009).
 32. Aarup, A. et al. Hypoxia-Inducible Factor-1α Expression in Macrophages Promotes Development of Atherosclerosis. Arteriosclerosis, 
Thrombosis, and Vascular Biology ATVBAHA. 116, 307830, doi:10.1161/ATVBAHA.116.307830 (2016).
Acknowledgements
We acknowledge the excellent technical assistance of Bente Emma Møller, Charlotte Wandel, and Birgitte Egedie 
Sander Nielsen. This study was funded by the Danish Heart foundation, grant number 13-04-R94-A4595-22777.
Author Contributions
A.A., I.B., L.B.N., and T.X.P. designed the study. A.A., C.H.N., L.S.B., H.H.E., and T.X.P. performed the 
experimental work. A.A., C.H.N., and L.S.B. analyzed the data. All authors critically revised and approved the 
manuscript.
Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-06816-6
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
